Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors
Conclusion This daily subcutaneous regimen of bortezomib showed a dose dependent plasma exposure, evidence of target inhibition and preliminary signs of clinical activity. However, cumulative neurological toxicity of this dose-dense daily regimen might preclude its further clinical development.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Anorexia | Asbestosis | Ataxia | Brain | Drugs & Pharmacology | Eating Disorders & Weight Management | Investigational New Drugs | Melanoma | Mesothelioma | Neurology | Skin Cancer | Study | Thrombocytopenia | Toxicology | Velcade